Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys - Wikidata - awgldk - TriplyDB

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

http://www.wikidata.org/entity/Q35729899

about

HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads Recent update in HIV vaccine development Immune correlates of vaccine protection against HIV-1 acquisition A Blueprint for HIV Vaccine Discovery Nonhuman primate models for HIV/AIDS vaccine development Using nonhuman primates to model HIV transmission Challenges in mucosal HIV vaccine development: lessons from non-human primate models A global approach to HIV-1 vaccine development HIV vaccine development: strategies for preclinical and clinical investigation Location and dynamics of the immunodominant CD8 T cell response to SIVΔnef immunization and SIVmac251 vaginal challenge Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells CD8 T cell response maturation defined by anentropic specificity and repertoire depth correlates with SIVΔnef-induced protection ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth HIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials.Perspectives for immunotherapy: which applications might achieve an HIV functional cure?Recent developments in clinical trial designs for HIV vaccine research DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus The Number and Complexity of Pure and Recombinant HIV-1 Strains Observed within Incident Infections during the HIV and Malaria Cohort Study Conducted in Kericho, Kenya, from 2003 to 2006 Immune-correlates analysis of an HIV-1 vaccine efficacy trial Systems serology for evaluation of HIV vaccine trials.Survivors Remorse: antibody-mediated protection against HIV-1.Low seroprevalent species D adenovirus vectors as influenza vaccines.HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform.Animal models for HIV/AIDS research HIV-1 Vaccine Trials: Evolving Concepts and Designs Langerin negative dendritic cells promote potent CD8+ T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays.CD8(+) T-cell effector function and transcriptional regulation during HIV pathogenesis Limited impact of passive non-neutralizing antibody immunization in acute SIV infection on viremia control in rhesus macaques.Immunopathogenesis of simian immunodeficiency virus infection in nonhuman primates Brief Report: HIV-1 gp120 T-Cell Responses Correspond to Infection Outcomes in the Global iPrEx Chemoprophylaxis Trial HIV-1 vaccines: challenges and new perspectives Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.Mucosal Vaccination with Heterologous Viral Vectored Vaccine Targeting Subdominant SIV Accessory Antigens Strongly Inhibits Early Viral Replication.Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy.Longitudinal requirement for CD4+ T cell help for adenovirus vector-elicited CD8+ T cell responses.Nonreplicating vectors in HIV vaccines.New directions for HIV vaccine development from animal models.Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys.

P2860

Q21131399-51227E2D-90A2-41DB-B863-47C4DC0209CD Q26766628-59D09D36-67E9-47AA-8174-0E8FA1D32ED2 Q26778573-D6A3E582-9623-4557-859E-9102D169DAAA Q26829865-A356983A-E54B-4F09-A115-F8437201827F Q26861148-C6F79D42-77DA-416C-AD66-8917EFE8B8B2 Q26861425-9E52EA5A-50DE-423B-9D38-41178DF67229 Q27022152-697A05E7-0B67-41C6-87CD-C36485DF5FB4 Q27024614-7A775E37-5744-4D55-92CF-7DABB4B1F238 Q27025917-2B656C31-AD6B-4A43-B40B-4A01B8B2C209 Q27301021-025E16FD-E28B-474C-8789-5FD66BF3E312 Q27320687-1930C13B-E53B-4CB0-8A62-B54CAF68BBE9 Q27321448-677EE46E-DF05-4CD0-94A6-D749BF457900 Q27342615-AA1B7063-36BC-4303-A63A-173241CB54F9 Q27676728-D696BE8C-EF44-4D96-8E8E-E80E2CEFF786 Q27687375-2D5017BA-18CA-4B50-BF0D-8E2BEAA28122 Q28078726-D5E7B76A-EBAA-45F7-9B9D-D26B14313D74 Q28083514-5BA90950-C4CC-4AF1-9013-843A36EE9C6D Q28554534-3C198BAD-6239-4BE2-A06B-9505D0434F29 Q28608652-43E917C7-4588-43C3-AE58-06957A931BA4 Q29617377-64252AC2-8E8F-48FA-AC28-F71016BD86E0 Q30238729-0874F7E4-B862-44E3-912F-6B2DC8670D2C Q30238730-848498F3-C395-4CA7-92A1-9CBA76F90329 Q30353263-898C7914-B7FD-4E32-B2C6-2A415290FFA6 Q30355260-F1D6AD8A-311A-4A3C-81F7-EC9648AF63D1 Q30422006-A83F16B2-E211-48A9-86F1-C59939D23B65 Q30423656-016897CF-6B6F-4E6A-9BD5-4CA929527560 Q30425520-61B5706C-B2B6-404B-8065-D648F26024C2 Q30426851-1DE6E4CB-28EB-49BA-B5F8-8FE0B6AF9699 Q30432007-410BA25E-E6A2-4B39-BC2F-E90660CDE7FB Q31138949-326B276C-77FA-4253-8F59-4ECB4E64DAB5 Q33355730-E961EB16-702E-446F-9A06-8754C0D699F3 Q33574027-5BF41CD9-F166-4DCC-9505-DCEE2881C5F4 Q33577972-298D49F9-9DAA-4546-83A1-E2917949DD77 Q33597744-E5DF3070-1EC3-4771-A088-8B944275745D Q33603602-661C837C-BBE4-411B-846E-3D6965DF7A52 Q33611645-3C284012-AD9A-4F81-9FED-A789A448876D Q33630150-EBA62788-9617-4851-A4D5-97783BCAF150 Q33693891-6A13CAFF-C2FE-4F5B-8703-554186A19ECC Q33767191-DB8D471F-F308-48CD-BDBF-37B7D3612128 Q33780980-5AAD634D-04C1-44F5-84C9-B37E02AC47C4

P2860

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

http://www.wikidata.org/entity/Q35729899

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Vaccine protection against acq ...... V challenges in rhesus monkeys

@ast

Vaccine protection against acq ...... V challenges in rhesus monkeys

@en

type

label

Vaccine protection against acq ...... V challenges in rhesus monkeys

@ast

Vaccine protection against acq ...... V challenges in rhesus monkeys

@en

prefLabel

Vaccine protection against acq ...... V challenges in rhesus monkeys

@ast

Vaccine protection against acq ...... V challenges in rhesus monkeys

@en

P1433

Q35729899-DD1856DC-E7AE-4CA0-9D74-5384079647AB

P1476

Q35729899-1161213D-54F9-4AAF-BFB2-861BCE00E95C

P2093

Q35729899-05486866-6025-4F42-96E9-CC430D1CF228

Q35729899-06363EDA-6410-4938-AC02-443B6727A244

Q35729899-12200FBF-34A6-420D-BA29-B7F8645E8675

Q35729899-148EF9D4-8E21-46F3-A294-CA51AAA79B81

Q35729899-1A82C65E-BB4D-4C39-8686-7B203DC6815A

Q35729899-20ECE991-23CC-4147-B405-309CEA5F9075

Q35729899-3A8C72F6-68B3-47E0-B721-25576EA3210A

Q35729899-62D918D7-7071-445B-A9B6-C8FED70A398B

Q35729899-685FD866-804C-40B8-B652-681C59FB1F2E

Q35729899-8131485D-A1FE-4028-982D-3BA23E9C2A7D

P2860

Q35729899-0A4132B0-8460-450D-B750-E6980AC84D80

Q35729899-155787C4-DB5D-4661-931A-53EA4CC86CDC

Q35729899-1CCA17BD-ADE6-4A5C-A856-4FA38A6CB019

Q35729899-1FA11F4B-C341-43D8-99A9-CFD8D08A7B83

Q35729899-1FE1761F-FF12-498B-9CE8-9BB095FCDAD1

Q35729899-35983712-3677-4EF0-92CC-FA0A34170670

Q35729899-40D3ACE1-5C0F-43A3-A0FD-8359E80B33F4

Q35729899-4255D98D-18B4-4E34-AFA3-E277399D017D

Q35729899-4C9E0AD7-BF17-4DB9-8E44-0310595EB5BB

Q35729899-5134931F-CAF4-4A35-9858-EC82CC369253

P2888

Q35729899-ED81E332-0EE4-4D93-B3D9-5182B1868DD5

P304

Q35729899-626D0E74-EE24-4DBA-AF16-6C4036DC7C10

P31

Q35729899-62926527-F351-456C-9211-0F5E76400183

P356

Q35729899-604056D3-E32B-452B-AFE0-FF0F072E1BFA

P407

Q35729899-151DCD30-8BB4-4157-A77A-3A4FA78E35C4

P433

Q35729899-D2EB33AB-82D9-4B80-A73C-61C9E846D977

P478

Q35729899-C73A1ECC-FC8A-437F-A931-B412F3152CFB

P50

Q35729899-26DAABC6-CA0E-4A7C-8A11-FF0F7D6D4254

Q35729899-2CC2B716-59BE-4ABF-B0B6-D3E67DE91331

Q35729899-8BB847C3-28BD-4A21-B1FC-88C4575E05EA

Q35729899-943D64F5-238D-4469-B423-2311B039668F

Q35729899-CE1DCDB7-ED5F-4668-AD5E-396E8A3CC82B

Q35729899-E7F780AC-A3A4-49F0-9CF7-6CACBDB5A190

Q35729899-EB3185B5-AED8-42B1-B680-19F3D9EE3BA8

Q35729899-F325F060-C480-49D4-8CB0-E4BAFB38F30C

P577

Q35729899-6A03DB84-7633-4CC7-AA90-2E116F580A79

P5875

Q35729899-08E49811-45E1-4ADA-BB1F-B36AEF523271

P6179

Q35729899-DD5C8171-5B39-469F-8A04-C73B483E8987

P698

Q35729899-C0E1296E-F9A8-4CB0-AB80-2E38E6D7CF8D

P932

Q35729899-9CF4A843-058F-4C58-9C26-7AE3544D3867

P356

P1433

P1476

Vaccine protection against acq ...... V challenges in rhesus monkeys

@en

P2093

Adam SanMiguel

http://www.w3.org/2001/XMLSchema#string

Angela Carville

http://www.w3.org/2001/XMLSchema#string

Diana M Lynch

http://www.w3.org/2001/XMLSchema#string

Donald N Forthal

http://www.w3.org/2001/XMLSchema#string

Donald Stablein

http://www.w3.org/2001/XMLSchema#string

Erik A Billings

http://www.w3.org/2001/XMLSchema#string

Hanneke Schuitemaker

http://www.w3.org/2001/XMLSchema#string

Hualin Li

http://www.w3.org/2001/XMLSchema#string

Ilnour Ourmanov

http://www.w3.org/2001/XMLSchema#string

Jerald C Sadoff

http://www.w3.org/2001/XMLSchema#string

P2860

TRIM5alpha Modulates Immunodeficiency Virus Control in Rhesus Monkeys

Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

Assessing vaccine effects in repeated low-dose challenge experiments.

Targeting early infection to prevent HIV-1 mucosal transmission.

Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys.

Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs

Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV

P2888

P304

89-93

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE10766

http://www.w3.org/2001/XMLSchema#string

P407

P433

7383

http://www.w3.org/2001/XMLSchema#string

P478

482

http://www.w3.org/2001/XMLSchema#string

P50

Lori F Maxfield

P577

2012-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51982696

http://www.w3.org/2001/XMLSchema#string

P6179

1051805279

http://www.w3.org/2001/XMLSchema#string

P698

22217938

http://www.w3.org/2001/XMLSchema#string

P932

3271177

http://www.w3.org/2001/XMLSchema#string